TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$214 Million


Follow-on Offering

Bookrunner, August 2017

MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to cardiovascular disease. With its aim to be the leading precision cardiovascular medicine company, MyoKardia develops therapies for heritable cardiomyopathies, which are rare, genetically-driven forms of heart failure that result in biomechanical defects in heart muscle contraction. There are no approved therapies for heritable cardiomyopathies as traditional cardiovascular drug development has focused on the broader heart failure population.